These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36157225)

  • 1. Tetrahydrocurcumin Chemosensitizes Breast Cancer to Albumin-Bound Paclitaxel by Enhancing SPARC Expression through Demethylation.
    Qiu D; Li X; Liu Y; Bao X; Ma L
    J Oncol; 2022; 2022():7961537. PubMed ID: 36157225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
    Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
    J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer.
    Yang M; Qu H; Liu A; Liu J; Sun P; Li H
    J Cancer Res Ther; 2019; 15(7):1561-1566. PubMed ID: 31939438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the relationship between secreted protein acidic and rich in cysteine expression level and therapeutic efficacy of nab-paclitaxel: a meta-analysis.
    Zhou X; Zhang L; Qierang C; Huang M; Yang X; Li L; Jiang J
    Transl Cancer Res; 2021 Feb; 10(2):876-885. PubMed ID: 35116417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
    Zang H; Li Y; Zhang X; Huang G
    Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy.
    Nakazawa Y; Nakazawa S; Kurozumi S; Ogino M; Koibuchi Y; Odawara H; Oyama T; Horiguchi J; Fujii T; Shirabe K
    Oncol Lett; 2020 Apr; 19(4):2705-2712. PubMed ID: 32218821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.
    Mirza S; Sharma G; Pandya P; Ralhan R
    Mol Cell Biochem; 2010 Sep; 342(1-2):101-9. PubMed ID: 20455010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.
    Pascual-Pasto G; Castillo-Ecija H; Unceta N; Aschero R; Resa-Pares C; Gómez-Caballero A; Vila-Ubach M; Muñoz-Aznar O; Suñol M; Burgueño V; Gomez-Gonzalez S; Sosnik A; Ibarra M; Schaiquevich P; de Álava E; Tirado OM; Mora J; Carcaboso AM
    J Control Release; 2022 Feb; 342():81-92. PubMed ID: 34974029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
    Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
    Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant methylation of secreted protein acidic and rich in cysteine gene and its significance in gastric cancer.
    Shao S; Zhou NM; Dai DQ
    World J Gastroenterol; 2019 Dec; 25(46):6713-6727. PubMed ID: 31857774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation of secreted protein, acidic and rich in cysteine in human laryngeal and hypopharyngeal carcinoma.
    He Q; Wei J; Zhang J; Jiang H; Wang S; Zhou X; Zhang Z; Huang G; Watanabe H; Su J
    Oncol Lett; 2011 Jul; 2(4):725-729. PubMed ID: 22848256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
    Tao L; Wu YQ; Zhang SP
    Neoplasma; 2019 Sep; 66(5):746-755. PubMed ID: 31169019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication.
    Zhang Y; Yang B; Du Z; Bai T; Gao YT; Wang YJ; Lou C; Wang FM; Bai Y
    World J Gastroenterol; 2012 May; 18(17):2043-52. PubMed ID: 22563191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant promoter methylation of SPARC in ovarian cancer.
    Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
    Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating the tumoral SPARC content to enhance albumin-based drug delivery for cancer therapy.
    Zheng B; Chen Y; Niu L; Zhang X; Yang Y; Wang S; Chen W; Cai Z; Huang W; Huang W
    J Control Release; 2024 Feb; 366():596-610. PubMed ID: 38184232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis.
    Liu C; Jiang F; Zhang X; Xu X
    Cancer Manag Res; 2020; 12():2777-2788. PubMed ID: 32425595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation-mediated expression of SPARC is correlated with tumor progression and poor prognosis of breast cancer.
    Li XL; Li JL; Qiu DJ; Ma L
    Neoplasma; 2022 Jul; 69(4):794-806. PubMed ID: 35400166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ-ABCB10 Contributes to Paclitaxel Resistance in Breast Cancer Through Let-7a-5p/DUSP7 Axis.
    Yang W; Gong P; Yang Y; Yang C; Yang B; Ren L
    Cancer Manag Res; 2020; 12():2327-2337. PubMed ID: 32273769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines.
    Guan X; Guan Y
    Neoplasma; 2020 Sep; 67(5):972-981. PubMed ID: 32412771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis.
    Ma J; Ma Y; Chen S; Guo S; Hu J; Yue T; Zhang J; Zhu J; Wang P; Chen G; Liu Y
    Biochem Biophys Res Commun; 2021 Jun; 558():134-140. PubMed ID: 33910127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.